Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)
- PMID: 21448904
- DOI: 10.1002/ijc.25947
Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)
Abstract
We aim to identify and characterize "escapes," men who developed metastasis and/or died from prostate cancer (PCa) despite screening, in the framework of the novel international ESCAPE-project. With this knowledge, the ultimate goal is to improve screening strategy. In this article, we focus on the study cohort of the European Randomized Study of Screening for Prostate Cancer (ERSPC), section Rotterdam. In all, 21,210 men were randomized to the screening arm of whom 19,950 were actually screened. The screening interval was 4 years. Men with prostate-specific antigen ≥3.0 ng/ml were recommended to undergo lateralized sextant prostate biopsy. The follow-up was complete until January 1, 2009. Of 19,950 screened men, 2,317 were diagnosed with PCa. Of these cancers 1,946 were detected in a screening round and 371 during an interval. The median follow-up was 11.1 years for the whole cohort and 7.3 years for men diagnosed with PCa. In total, we identified 168 escapes among 2,317 cancers (7.3%) within our screening cohort of 19,950 men (0.8%). More than half of these escapes were found in the initial screening round (94 of 168). Possible mechanisms behind escaping are nonattending, inadequate screening tests, the relative long screening interval, the age cut-off at 75 years, and undertreatment. International cooperation is crucial to compare the escapes of our cohort with other study groups participating in the ESCAPE-project which have different, more aggressive screening strategies. Subsequently, we can achieve improvements of the current screening algorithm, which hopefully will further decrease PCa-specific mortality without increasing overdiagnosis and overtreatment.
Copyright © 2011 UICC.
Similar articles
-
Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.Eur Urol. 2011 Aug;60(2):330-6. doi: 10.1016/j.eururo.2011.05.013. Epub 2011 May 17. Eur Urol. 2011. PMID: 21601352 Clinical Trial.
-
Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.BJU Int. 2012 Dec;110(11):1654-60. doi: 10.1111/j.1464-410X.2012.11481.x. Epub 2012 Oct 8. BJU Int. 2012. PMID: 23043563 Clinical Trial.
-
No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).Urology. 2004 May;63(5):892-7; discussion 897-9. doi: 10.1016/j.urology.2003.12.042. Urology. 2004. PMID: 15134973 Clinical Trial.
-
Overall and disease-specific survival of patients with screen-detected prostate cancer in the European randomized study of screening for prostate cancer, section Rotterdam.Eur Urol. 2007 Feb;51(2):366-74; discussion 374. doi: 10.1016/j.eururo.2006.07.052. Epub 2006 Aug 15. Eur Urol. 2007. PMID: 16930812 Review.
-
Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Can J Urol. 2005. PMID: 15780157 Review.
Cited by
-
Variable metastatic potentials correlate with differential plectin and vimentin expression in syngeneic androgen independent prostate cancer cells.PLoS One. 2013 May 22;8(5):e65005. doi: 10.1371/journal.pone.0065005. Print 2013. PLoS One. 2013. PMID: 23717685 Free PMC article.
-
Screening for prostate cancer.Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Cochrane Database Syst Rev. 2013. PMID: 23440794 Free PMC article.
-
Risk-based prostate cancer screening.Eur Urol. 2012 Apr;61(4):652-61. doi: 10.1016/j.eururo.2011.11.029. Epub 2011 Nov 24. Eur Urol. 2012. PMID: 22134009 Free PMC article. Review.
-
iTRAQ identification of candidate serum biomarkers associated with metastatic progression of human prostate cancer.PLoS One. 2012;7(2):e30885. doi: 10.1371/journal.pone.0030885. Epub 2012 Feb 15. PLoS One. 2012. PMID: 22355332 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical